Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a testosterone propionate-induced C57BL/6 mouse model of androgenetic alopecia, demonstrating that high-dose, prolonged testosterone administration inhibited hair regrowth and mirrored human AGA pathology, providing a useful platform for studying hair loss mechanisms and testing therapies targeting the Wnt/β-catenin pathway.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This study developed a microneedle system using black phosphorus nanosheets and baicalin for treating androgenetic alopecia, finding it effectively enhanced drug penetration and follicular targeting while showing synergistic efficacy and safety in preclinical tests, including in vivo model efficacy against testosterone-induced hair loss.

In a testosterone-induced mouse model, this study found that exosomes from injectable Platelet-Rich Fibrin (i-PRF) significantly reduced inflammation, oxidative stress, and apoptosis, while enhancing hair regeneration, with the greatest improvements seen when combined with minoxidil, suggesting potential as a novel treatment for androgenetic alopecia.

Tanshinone Capsule may help regrow hair by boosting specific cell signals.

In this study, Allium macrostemon Bunge extract was found to promote hair regrowth in a testosterone-induced androgenetic alopecia mouse model by activating Wnt/β-catenin signaling and boosting hair dermal papilla cell proliferation and growth factor expression.

This study observed that CXCL12 is highly co-expressed with androgen receptors in human hair follicle cells, and its inhibition via antibodies increased hair length, suggesting a potential treatment strategy for androgenic alopecia.

In this study, 2′‐Fucosyllactose (2′‐FL) administration significantly reduced hair loss and increased hair length and thickness in a testosterone-induced androgenic alopecia mouse model, suggesting potential as a therapeutic agent for AGA.

This study found that Tanshinone I and Tanshinone IIA from Salviae Miltiorrhizae Radix inhibited Nox activity heightened by testosterone in a mouse model, reducing H₂O₂ production and cell apoptosis, and reversing testosterone-induced hair growth suppression, suggesting their potential as treatments for androgenetic alopecia.

This study found that 1′S-1′-acetoxychavicol acetate from Alpinia galanga inhibits Nox isozymes and suppresses testosterone-induced hair loss in a mouse model of androgenetic alopecia.

In a testosterone-induced mouse model of androgenetic alopecia, this study found that oral and topical administration of Connarus semidecandrus Jack ethanol extract promoted hair regrowth and improved hair health markers similar to finasteride, without detectable liver or kidney toxicity.

This study concluded that S. hexaphylla extract may improve androgenetic alopecia by reducing 5α-reductase and androgen receptor levels, inhibiting apoptosis, and promoting keratinocyte proliferation in experimental models.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

This study found that in a mouse model of androgenetic alopecia, topical application of finasteride-loaded Platycladi cacumen-derived nanovesicles improved hair regrowth more effectively than minoxidil.

This study found that an extract from Justicia procumbens may prevent hair loss in a mouse model of androgenic alopecia by enhancing hair follicle cell proliferation and improving hair characteristics.

This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.

In this study, researchers found that topical apigenin promoted hair growth in a testosterone-induced alopecia mouse model, with effects comparable to minoxidil, suggesting a potential treatment approach for androgenetic alopecia through the Wnt signaling pathway.

This study found that TSG-enriched Polygonum multiflorum extract, optimized through microwave-assisted and chromatographic methods, promotes hair regrowth in a mouse model of androgenetic alopecia via 5α-reductase inhibition and Wnt/β-catenin pathway activation, suggesting its potential as a natural treatment.

This study found that external application of DGD activates the Wnt/β-catenin signaling pathway, promoting hair follicle anagen phase entry, and is a more effective and safer treatment for androgenetic alopecia in mice compared to oral administration.

This study developed a dissolvable microneedle system delivering specific molecules to remodel lymphatic networks and normalize metabolic processes, which accelerated hair growth and activated hair follicle stem cells in a mouse model of androgenetic alopecia.

This study developed a gas-propelled microneedle patch with puerarin/quercetin nanoparticles, which demonstrated improved hair-regenerating effects in an androgenetic alopecia mouse model by increasing drug delivery, alleviating oxidative stress, promoting angiogenesis, and rejuvenating senescent cells.

In this study, 1'-S-1'-acetoxychavicol acetate (ACA) from Alpinia galanga showed potential in suppressing testosterone-induced hair loss by inhibiting Nox isozymes in a mouse model of androgenetic alopecia.

Testosterone causes hair loss in AGA mice, which are good for testing baldness treatments, and both minoxidil and cyproterone acetate can prevent this hair loss.

This study found that blocking the chemokine CXCL12 in a testosterone-induced mouse model of androgenetic alopecia restored hair regeneration and reduced fibrosis and immune alterations.

This study found that a 2-deoxy-D-ribose gel stimulated hair follicle growth in mice with androgenic alopecia, showing effects similar to minoxidil without additional benefits from combining the two treatments.

In this study, compound glycyrrhizin promoted hair regrowth in a testosterone-induced alopecia mouse model and increased human hair dermal papilla cell proliferation, likely through activating the Wnt/β-catenin pathway.

In testosterone-induced AGA mouse models, this study found that a dual-drug-loaded cationic nanoemulsion of minoxidil and finasteride enhanced follicle-associated retention, supporting hair regeneration while reducing systemic absorption and showing good skin compatibility, indicating a promising approach for androgenetic alopecia treatment.

This study found that transdermal delivery of finasteride using biomimetic Platycladi cacumen-derived nanovesicles enhanced hair regrowth in a mouse model of androgenetic alopecia, outperforming minoxidil by improving skin permeation, reducing oxidative stress, and boosting local drug retention.

This study demonstrated that Celtis choseniana Nakai may help alleviate androgenic alopecia by enhancing hair regrowth and activating Wnt/β-catenin signaling in both a mouse model and cultured human cells.

In this study, researchers developed a probiotic-based microneedle system combining Weissella cibaria and clascoterone to target androgenetic alopecia, which in a mouse model improved hair density, vascular regeneration, and reduced inflammation, suggesting a promising treatment approach.